)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Dicot
Dicot (DICOT) investor relations material
Dicot Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Completed a capital raise of SEK 231 million, strengthening financial position for phase 2b study of LIB-01 targeting erectile dysfunction.
FDA clearance received to initiate Part I of phase 2b study in the US; Clinical Trial Application submitted in EU.
LIB-01 abstracts accepted for oral presentation at SMSNA annual conference, highlighting scientific interest.
Manufacturing of LIB-01 tablets completed; preparations for clinical trial advanced.
Financial highlights
Net sales were MSEK 0.0 for both Q2 and H1 2026, unchanged year-over-year.
Result after financial items: MSEK -18.4 for Q2 2026 (vs. -24.3 Q2 2025); MSEK -33.2 for H1 2026 (vs. -47.2 H1 2025).
Earnings per share: SEK -0.01 for Q2 2026 (unchanged YoY); SEK -0.02 for H1 2026 (vs. -0.03 H1 2025).
Operating expenses for Q2 2026 were SEK 18.7 million, down from SEK 25.0 million in Q2 2025.
Cash and cash equivalents at June 30, 2026: SEK 248.4 million (vs. SEK 105.8 million a year earlier).
Outlook and guidance
Phase 2b study of LIB-01 to be initiated in H2 2026 in both US and Europe.
Additional preclinical toxicology study accelerated to meet FDA requirements.
Company aims to establish industrial partnerships for out-licensing ahead of phase 3.
Explain LIB-01 preclinical study acceleration
Detail geographic variation in out-licensing
Discuss significance of SMSNA presentations
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dicot
- Over 80% of the rights issue is secured, ensuring funding for the planned phase 2b study.DICOT
Investor update - Phase 2b fully funded via SEK 210M rights issue; net loss narrows as LIB-01 advances.DICOTQ1 2026
- LIB-01's phase 2a success drives clinical progress, but further funding is needed for phase 2b.DICOTQ4 2025
- LIB-01's Phase 2a success and strong cash position set the stage for next clinical milestones.DICOTQ3 2025
- Phase 2a study enrollment completed; strong cash position supports next development steps.DICOTQ2 2025
- LIB-01 phase 2a trial fully funded after oversubscribed rights issue; Nasdaq listing approved.DICOTQ3 2024
- Phase 2a for LIB-01 is fully funded after a 65%-secured SEK 122.6M rights issue.DICOTQ2 2024
- Strong warrant uptake and robust cash position support ongoing LIB-01 clinical progress.DICOTQ1 2025
- LIB-01 advanced to phase 2a with robust funding and new US patents, positioning for growth.DICOTQ4 2024
Next Dicot earnings date
Q3 202628 Oct, 2026
Dicot
Next Dicot earnings date
Q3 202628 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage